JP5981141B2 - 多臓器不全症候群（ｍｏｄｓ）の予防および／または処置のためのインターロイキン−２２の使用 - Google Patents

多臓器不全症候群（ｍｏｄｓ）の予防および／または処置のためのインターロイキン−２２の使用 Download PDF

Info

Publication number
JP5981141B2
JP5981141B2 JP2011545498A JP2011545498A JP5981141B2 JP 5981141 B2 JP5981141 B2 JP 5981141B2 JP 2011545498 A JP2011545498 A JP 2011545498A JP 2011545498 A JP2011545498 A JP 2011545498A JP 5981141 B2 JP5981141 B2 JP 5981141B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
multiple organ
subject
organ dysfunction
mods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011545498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515165A (ja
JP2012515165A5 (enExample
Inventor
リャン ファン，ユウ
リャン ファン，ユウ
ファ ファン，ツィー
ファ ファン，ツィー
スン，チー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generon Shanghai Corp Ltd
Original Assignee
Generon Shanghai Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generon Shanghai Corp Ltd filed Critical Generon Shanghai Corp Ltd
Publication of JP2012515165A publication Critical patent/JP2012515165A/ja
Publication of JP2012515165A5 publication Critical patent/JP2012515165A5/ja
Application granted granted Critical
Publication of JP5981141B2 publication Critical patent/JP5981141B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2011545498A 2009-01-12 2010-01-11 多臓器不全症候群（ｍｏｄｓ）の予防および／または処置のためのインターロイキン−２２の使用 Expired - Fee Related JP5981141B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14413409P 2009-01-12 2009-01-12
US61/144,134 2009-01-12
PCT/US2010/020673 WO2010081112A1 (en) 2009-01-12 2010-01-11 Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22

Publications (3)

Publication Number Publication Date
JP2012515165A JP2012515165A (ja) 2012-07-05
JP2012515165A5 JP2012515165A5 (enExample) 2013-02-28
JP5981141B2 true JP5981141B2 (ja) 2016-08-31

Family

ID=42316862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011545498A Expired - Fee Related JP5981141B2 (ja) 2009-01-12 2010-01-11 多臓器不全症候群（ｍｏｄｓ）の予防および／または処置のためのインターロイキン−２２の使用

Country Status (7)

Country Link
US (1) US8956605B2 (enExample)
EP (1) EP2385841B1 (enExample)
JP (1) JP5981141B2 (enExample)
CN (1) CN102348463B (enExample)
AU (1) AU2010203446B2 (enExample)
CA (1) CA2748392C (enExample)
WO (1) WO2010081112A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
EP4106794A4 (en) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd METHOD FOR TREATING TRANSPLANT AND HOST DISEASE
CN112007146A (zh) * 2020-09-03 2020-12-01 上海市儿童医院 Il-22在治疗和/或预防脓毒症诱发的肝脏损伤的药物中的用途
WO2022191828A1 (en) * 2021-03-10 2022-09-15 Wen Tan NEW USE OF (R)-β2-AGONISTS IN TREATMENT OF SEPSIS AND ACUTE RESPIRATORY DISTRESS SYNDROME

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516103A (ja) 1998-05-29 2002-06-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド インターロイキン２１およびインターロイキン２２
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US7226591B2 (en) * 2000-05-22 2007-06-05 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
CN101472611A (zh) * 2006-06-19 2009-07-01 惠氏公司 调节il-22和il-17的方法
WO2008085229A2 (en) * 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
CN101168049A (zh) * 2007-10-23 2008-04-30 中国人民解放军军事医学科学院基础医学研究所 白介素-22在制备治疗肝病药物中的应用及其制备方法

Also Published As

Publication number Publication date
US20110268696A1 (en) 2011-11-03
WO2010081112A1 (en) 2010-07-15
CA2748392A1 (en) 2010-07-15
EP2385841A4 (en) 2012-12-19
AU2010203446B2 (en) 2015-12-17
CA2748392C (en) 2017-06-27
CN102348463A (zh) 2012-02-08
AU2010203446A1 (en) 2011-07-14
EP2385841A1 (en) 2011-11-16
JP2012515165A (ja) 2012-07-05
EP2385841B1 (en) 2016-11-16
CN102348463B (zh) 2014-05-07
US8956605B2 (en) 2015-02-17

Similar Documents

Publication Publication Date Title
US8956605B2 (en) Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22
JP7590724B2 (ja) 炎症性腸疾患の治療薬
US10335455B2 (en) Method for prevention or treatment of intractable inflammatory bowel disease
HU229045B1 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
MX2013005641A (es) Composiciones anti-inflamatorias.
JP6023803B2 (ja) 神経変性及び虚血性脳疾患を処置するための化合物及び薬学的組合せ
JP7163547B2 (ja) 新規ペプチドおよびその用途
KR102009932B1 (ko) 허혈로 인한 뉴런 손상을 감소시키기 위한 아포에쿼린
TW201302214A (zh) 治療或預防皮膚癌之類鋅手指胜肽、其表現質體、及包含其之醫藥組成物
AU2007226130B2 (en) Use of caspases for the preparation of medicaments
JP2012504941A5 (enExample)
RU2690677C1 (ru) Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью
JP4748639B2 (ja) 肝臓疾患治療剤
AU2008226337A1 (en) Method for treating cancer via the mucosal administration of interleukin
CN108853483B (zh) 经修饰的胸腺素β4在治疗脑缺血再灌注损伤方面的用途
CN120939206A (zh) Metrnl蛋白与氯吡格雷联合治疗血栓的药物组合物及其应用
HK40092198A (en) A drug for the treatment and prevention of cancer and its applications
HK40092198B (en) A drug for the treatment and prevention of cancer and its applications
CN118236470A (zh) MOTS-c肽及其衍生物在制备支气管哮喘治疗药物中的应用
EP3181144A1 (en) Medicinal composition for treating and/or preventing esophageal stenosis
JP2001151692A (ja) イヌパルボウイルス感染症治療方法および治療剤
MXPA01012663A (es) Uso de interleucina-11 para tratar el shock hemorragico.
WO2001080877A1 (en) Preventives for reinfection after liver transplantation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160728

R150 Certificate of patent or registration of utility model

Ref document number: 5981141

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees